Mangalam Drugs commissions intermediate manufacturing facility
This will enable Mangalam to reduce its reliability on Chinese imports for this product and also help to maintain an uninterrupted supply chain to a great extent
This will enable Mangalam to reduce its reliability on Chinese imports for this product and also help to maintain an uninterrupted supply chain to a great extent
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
Mucormycosis drug AmphoTLC will be imported from Taiwan by Stelis Biopharma Private Limited (Stelis), the biotech arm of Strides group, and will be launched and distributed in India immediately by Strides
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
The product patent has been already filed under fast track approval
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
Natco has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for Covid-19 in India
Subscribe To Our Newsletter & Stay Updated